GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Return-on-Tangible-Asset

Clearmind Medicine (Clearmind Medicine) Return-on-Tangible-Asset : -77.07% (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Clearmind Medicine's annualized Net Income for the quarter that ended in Jan. 2024 was $-5.47 Mil. Clearmind Medicine's average total tangible assets for the quarter that ended in Jan. 2024 was $7.10 Mil. Therefore, Clearmind Medicine's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2024 was -77.07%.

The historical rank and industry rank for Clearmind Medicine's Return-on-Tangible-Asset or its related term are showing as below:

CMND' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -263.59   Med: -110.83   Max: -49.54
Current: -116.35

During the past 7 years, Clearmind Medicine's highest Return-on-Tangible-Asset was -49.54%. The lowest was -263.59%. And the median was -110.83%.

CMND's Return-on-Tangible-Asset is ranked worse than
82.33% of 1545 companies
in the Biotechnology industry
Industry Median: -40.36 vs CMND: -116.35

Clearmind Medicine Return-on-Tangible-Asset Historical Data

The historical data trend for Clearmind Medicine's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Return-on-Tangible-Asset Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -49.54 -119.23 -100.23 -224.46 -263.59

Clearmind Medicine Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -302.39 -138.01 -45.71 -298.03 -77.07

Competitive Comparison of Clearmind Medicine's Return-on-Tangible-Asset

For the Biotechnology subindustry, Clearmind Medicine's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearmind Medicine's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Return-on-Tangible-Asset falls into.



Clearmind Medicine Return-on-Tangible-Asset Calculation

Clearmind Medicine's annualized Return-on-Tangible-Asset for the fiscal year that ended in Oct. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Oct. 2023 )  (A: Oct. 2022 )(A: Oct. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Oct. 2023 )  (A: Oct. 2022 )(A: Oct. 2023 )
=-6.234/( (0.511+4.219)/ 2 )
=-6.234/2.365
=-263.59 %

Clearmind Medicine's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=-5.472/( (4.219+9.981)/ 2 )
=-5.472/7.1
=-77.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jan. 2024) net income data.


Clearmind Medicine  (NAS:CMND) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Clearmind Medicine Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearmind Medicine (Clearmind Medicine) Business Description

Traded in Other Exchanges
Address
101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Clearmind Medicine (Clearmind Medicine) Headlines

From GuruFocus